In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL

Blood Cancer J. 2017 Sep 8;7(9):e604. doi: 10.1038/bcj.2017.87.
No abstract available

Publication types

  • Letter

MeSH terms

  • Dasatinib / pharmacology*
  • Dose-Response Relationship, Drug
  • Drug Screening Assays, Antitumor
  • Humans
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology

Substances

  • Dasatinib